蔡佳龍¹、林嘉祥^1,2、陳忠賢^1,2、吳振宇^1,2、陳毓騏^1,2、吳俊賢^1,2、楊堉麟³

義大醫院 泌尿科¹；義守大學²；中華醫事科技大學^3,

Chia-Lung Tsai¹, Victor C. Lin^1,2, Chung-Hsien Chen^1,2, Richard Chen-Yu Wu^1,2,

Yu-Chi Chen^1,2, Chun-Hsien Wu^1,2, Yu-Lin Yang^3,

Department of Urology, E-Da Hospital¹; I-Shou University²; Chung Hwa University of Medical³

 

Purpose: Bladder cancer is the most common malignant tumor involving the urinary system and the morbidity is increasing year by year. Treatment for bladder cancer depends on early diagnosis and surgical resection. However, the effective treatment for bladder cancer is still poor. Salidroside is the main compound from Rhodiola rosea, a widely used Chinese herb, and has been reported to possess anti-tumor effect. However, the therapeutic effect of Salidroside in bladder cancer remains unclear.

Materials and Methods: Bladder cancer cells (T24 cells) were treated with Salidroside (12.5, 25, and 50μg/ml) for 24 h followed by the serial biological examination.

Results: Salidroside reduced not only the viability but also cell proliferation of bladder cancer cells by trypan blue exclusion assay and MTT assay. Salidroside induced cytotoxicity of bladder cancer cells according to LDH assay. However, Salidroside does not affects the BMP-2 secretion in T24 cells. In addition, the TGF-β pathway is involved in urinary bladder cancer progression. Salidroside significantly reduced the expression of TGF-β1 secretion in T24 cells. Salidroside significantly decreased TGF-β1 signaling, in addition to inducing a marked increase in the down-regulation of Smad7. Moreover, Salidroside decreased migration in bladder cancer cells. More importantly, Salidroside decrease EMT (Epithelial-mesenchymal transition), since it decreases the expression of α-SMA and increase expression of E-cadherin.

Conclusion: To sum up, Salidroside may act as a novel anti-cancer agent by down-regulating TGF-β1 signaling and modulating EMT.